迈威生物(688062.SH)：注射用7MW4911临床试验申请获批

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its innovative antibody-drug conjugate (ADC) 7MW4911, targeting CDH17, a promising therapeutic target in various gastrointestinal cancers [1] Group 1: Company Developments - The clinical trial approval for 7MW4911 marks a significant milestone for the company, showcasing its capabilities in developing novel therapeutics based on its proprietary IDDC™ antibody conjugation technology platform [1] - 7MW4911 specifically targets calcium adhesion protein 17 (CDH17), which is overexpressed in colorectal cancer, gastric cancer, and pancreatic cancer, indicating its potential for precision intervention in these malignancies [1] Group 2: Industry Context - CDH17 has been validated as a potential therapeutic target through multi-omics studies across various cancer types, highlighting its relevance in the oncology landscape [1] - The abnormal high expression of CDH17 is closely associated with tumor invasion, metastasis, and poor prognosis, making it an ideal target for therapeutic intervention in gastrointestinal malignancies [1]